OTCMKTS:PZRXQ

PhaseRx Competitors

$0.03
0.00 (0.00 %)
(As of 04/14/2021 11:53 AM ET)
Add
Compare
Today's Range
$0.03
Now: $0.03
$0.03
50-Day Range
$0.01
MA: $0.03
$0.04
52-Week Range
$0.00
Now: $0.03
$0.08
Volume105 shs
Average Volume37,547 shs
Market Capitalization$298,095.00
P/E RatioN/A
Dividend YieldN/A
Beta-0.86

Competitors

PhaseRx (OTCMKTS:PZRXQ) Vs. COTQF, TLOG, AOLS, AOXG, PPCB, and ANTH

Should you be buying PZRXQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to PhaseRx, including Cotinga Pharmaceuticals (COTQF), TetraLogic Pharmaceuticals (TLOG), Aeolus Pharmaceuticals (AOLS), Aoxing Pharmaceutical (AOXG), Propanc Biopharma (PPCB), and Anthera Pharmaceuticals (ANTH).

PhaseRx (OTCMKTS:PZRXQ) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Earnings and Valuation

This table compares PhaseRx and Cotinga Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PhaseRxN/AN/AN/AN/AN/A
Cotinga PharmaceuticalsN/AN/A$-2,050,000.00N/AN/A

Profitability

This table compares PhaseRx and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PhaseRxN/AN/AN/A
Cotinga PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for PhaseRx and Cotinga Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PhaseRx0000N/A
Cotinga Pharmaceuticals0000N/A

Volatility and Risk

PhaseRx has a beta of -0.86, suggesting that its stock price is 186% less volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, suggesting that its stock price is 4,244% more volatile than the S&P 500.

Summary

Cotinga Pharmaceuticals beats PhaseRx on 1 of the 1 factors compared between the two stocks.

PhaseRx (OTCMKTS:PZRXQ) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Profitability

This table compares PhaseRx and TetraLogic Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PhaseRxN/AN/AN/A
TetraLogic PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for PhaseRx and TetraLogic Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PhaseRx0000N/A
TetraLogic Pharmaceuticals0000N/A

Earnings & Valuation

This table compares PhaseRx and TetraLogic Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PhaseRxN/AN/AN/AN/AN/A
TetraLogic PharmaceuticalsN/AN/AN/AN/AN/A

Volatility & Risk

PhaseRx has a beta of -0.86, indicating that its share price is 186% less volatile than the S&P 500. Comparatively, TetraLogic Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Summary

TetraLogic Pharmaceuticals beats PhaseRx on 1 of the 1 factors compared between the two stocks.

Aeolus Pharmaceuticals (OTCMKTS:AOLS) and PhaseRx (OTCMKTS:PZRXQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Aeolus Pharmaceuticals and PhaseRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aeolus PharmaceuticalsN/AN/AN/A
PhaseRxN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Aeolus Pharmaceuticals and PhaseRx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aeolus Pharmaceuticals0000N/A
PhaseRx0000N/A

Volatility & Risk

Aeolus Pharmaceuticals has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500. Comparatively, PhaseRx has a beta of -0.86, indicating that its share price is 186% less volatile than the S&P 500.

Earnings and Valuation

This table compares Aeolus Pharmaceuticals and PhaseRx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aeolus PharmaceuticalsN/AN/AN/AN/AN/A
PhaseRxN/AN/AN/AN/AN/A

Summary

Aeolus Pharmaceuticals beats PhaseRx on 1 of the 1 factors compared between the two stocks.

Aoxing Pharmaceutical (OTCMKTS:AOXG) and PhaseRx (OTCMKTS:PZRXQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Aoxing Pharmaceutical and PhaseRx, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aoxing Pharmaceutical0000N/A
PhaseRx0000N/A

Earnings & Valuation

This table compares Aoxing Pharmaceutical and PhaseRx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aoxing PharmaceuticalN/AN/AN/AN/AN/A
PhaseRxN/AN/AN/AN/AN/A

Profitability

This table compares Aoxing Pharmaceutical and PhaseRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aoxing PharmaceuticalN/AN/AN/A
PhaseRxN/AN/AN/A

Volatility and Risk

Aoxing Pharmaceutical has a beta of 3.26, indicating that its share price is 226% more volatile than the S&P 500. Comparatively, PhaseRx has a beta of -0.86, indicating that its share price is 186% less volatile than the S&P 500.

Summary

Aoxing Pharmaceutical beats PhaseRx on 1 of the 1 factors compared between the two stocks.

PhaseRx (OTCMKTS:PZRXQ) and Propanc Biopharma (OTCMKTS:PPCB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.

Profitability

This table compares PhaseRx and Propanc Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PhaseRxN/AN/AN/A
Propanc BiopharmaN/AN/A-4,812.81%

Valuation & Earnings

This table compares PhaseRx and Propanc Biopharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PhaseRxN/AN/AN/AN/AN/A
Propanc BiopharmaN/AN/A$-4,740,000.00N/AN/A

Analyst Ratings

This is a summary of current ratings for PhaseRx and Propanc Biopharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PhaseRx0000N/A
Propanc Biopharma0000N/A

Volatility & Risk

PhaseRx has a beta of -0.86, indicating that its stock price is 186% less volatile than the S&P 500. Comparatively, Propanc Biopharma has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.

PhaseRx (OTCMKTS:PZRXQ) and Anthera Pharmaceuticals (OTCMKTS:ANTH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for PhaseRx and Anthera Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PhaseRx0000N/A
Anthera Pharmaceuticals0000N/A

Profitability

This table compares PhaseRx and Anthera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PhaseRxN/AN/AN/A
Anthera PharmaceuticalsN/AN/AN/A

Earnings & Valuation

This table compares PhaseRx and Anthera Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PhaseRxN/AN/AN/AN/AN/A
Anthera PharmaceuticalsN/AN/AN/AN/AN/A

Volatility & Risk

PhaseRx has a beta of -0.86, indicating that its stock price is 186% less volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500.

Summary

Anthera Pharmaceuticals beats PhaseRx on 1 of the 1 factors compared between the two stocks.


PhaseRx Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05flat$1.12 millionN/A-0.57Decrease in Short Interest
News Coverage
Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04flat$1.11 millionN/A0.00Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$1.07 millionN/A0.00Increase in Short Interest
News Coverage
AOXG
Aoxing Pharmaceutical
0.5$0.02flat$1.05 millionN/A0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.21flat$1.03 millionN/A0.00Decrease in Short Interest
Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07flat$970,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
SPHS
Sophiris Bio
0.1$0.03flat$965,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08flat$872,000.00$250,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01flat$772,000.00N/A0.00Gap Up
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.02flat$749,000.00N/A0.00News Coverage
Gap Up
PXYN
Praxsyn
0.6$0.00flat$678,000.00N/A0.00Increase in Short Interest
Gap Down
SKVI
Skinvisible
0.7$0.15flat$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05flat$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.15flat$458,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.17flat$436,000.00N/A0.00
HSTC
HST Global
0.8$0.07flat$378,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00News Coverage
Gap Up
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01flat$319,000.00N/A0.00Increase in Short Interest
Gap Down
WDBG
Woodbrook Group
0.0$1.60flat$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.09flat$124,000.00N/A0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.02flat$118,000.00$20,000.000.00
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00flat$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00flat$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02flat$8,000.00$110,000.000.00Decrease in Short Interest
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.09flat$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50flat$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49flat$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$35.36flat$0.00N/A0.00Decrease in Short Interest
News Coverage
Gap Down
HRBR
Harbor Diversified
0.0$1.15flat$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00Gap Up
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Up
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00Decrease in Short Interest
News Coverage
Gap Up
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00High Trading Volume
Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.07flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00High Trading Volume
Gap Up
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.05flat$0.00$26.09 million0.00Increase in Short Interest
News Coverage
Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.04flat$0.00N/A0.00Increase in Short Interest
News Coverage
Gap Down
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.